Vera Therapeutics, Inc. Notes Payable
Vera Therapeutics, Inc. (VERA) had Notes Payable of $75.00 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:NotesPayable · last filed 2026-08-10
- 2026-06-30: Notes Payable $75.00M.
- 2026-03-31: Notes Payable $75.00M.
- 2025-12-31: Notes Payable $75.00M.
- 2025-09-30: Notes Payable $75.00M.
| Period end | Notes Payable |
|---|---|
| 2026-06-30 | $75.00M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $75.00M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $75.00M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $75.00M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $75.00M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $50.00M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $50.00M 10-K · filed 2026-02-26 |
| 2024-09-30 | $50.00M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $50.00M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $50.00M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $50.00M 10-K · filed 2025-02-28 |
| 2023-09-30 | $25.00M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $25.00M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $25.00M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $25.00M 10-K · filed 2024-03-27 |
| 2021-12-31 | $5.00M 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |